Randomized Phase-II Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Abiraterone acetate (Primary) ; Gonadotropin releasing hormone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms SPARE
- 24 Jan 2018 Planned End Date changed from 1 Oct 2016 to 1 Oct 2018.
- 24 Jan 2018 Planned primary completion date changed from 1 Apr 2016 to 1 Mar 2018.
- 24 Jan 2018 Status changed from recruiting to active, no longer recruiting.